Outcome Following Percutaneous Transhepatic Biliary Drainage (PTBD) in Carcinoma Gallbladder: a Prospective Observational Study

Vanji Nathan Subramani1 · Mohanasundaram Avudaiappan2 · Thakur Deen Yadav2 · Hemanth Kumar1 · Vishal Sharma3 · Harshal Mandavdhare3 · Ujjwal Gors4 · Harjeet Singh* · Harjeet Singh

Accepted: 17 June 2021 / Published online: 26 June 2021
© Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract
Introduction Percutaneous biliary drainage (PTBD) is required as palliation and optimization for surgery or chemotherapy in carcinoma gallbladder (GBC) but may be associated with complications. We aimed to study the outcomes, complications, and changes in quality of life in patients with GBC undergoing PTBD.

Methods A prospective study from July 2018 to December 2019 in patients of GBC presenting with obstructive jaundice was done. Patients planned for PTBD were included in the study. The progression of the disease, complications of PTBD, reinterventions, effects on initiation or completion of chemotherapy, surgical resection or intervention, and overall survival were recorded. Quality of life (QoL) was assessed using the SF-36 questionnaire before and after 4–6 weeks of intervention.

Results Of 160 patients assessed for inclusion, 60 (mean age 53.7 ± 10.95 years, 27 (45%) males) were eventually included. Eleven patients (18.3%) had metastatic disease at presentation. Of 60 patients undergoing PTBD, none had immediate procedure-related complications, 41 (68%) patients had at least one, and 18 (30%) patients had more than one complication. The most common complication was peri-catheter bile leak (41.6%), followed by catheter dislodgement (30%), blockage (23.3%), and bleeding (10%). Reintervention was required in 32 (53%) patients. There was a significant decrease in QoL after PTBD (P < 0.0001). Median survival after PTBD was 12 weeks.

Conclusion The high technical success of PTBD does not translate into the improvement of QoL.

Keywords Gallbladder cancer · Biliary drainage · Complication · Quality of life · Jaundice

Introduction

Gallbladder cancer (GBC) is associated with a poor prognosis, with overall survival ranging from only 5 to 20% [1, 2]. Jaundice is an ominous sign in GBC and is present in 30–60% of patients at the time of presentation [3–5]. Jaundice in carcinoma gallbladder is due to one of the following reasons: (a) invasion of the common bile duct (CBD) by a mass in the neck of the gallbladder, (b) invasion of the hilum by an infiltrating mass, (c) lymph node compression, (d) intraluminal tumor extension, and (e) extensive liver metastasis or due to an incidental stone in the CBD [6–8].

Most patients presenting with jaundice are not amenable to curative surgical resection. Hence, effective palliation plays a prominent role in the management of these patients [8–12]. Biliary drainage is the most important component of palliation, especially in patients with persistent pruritus, anorexia, and cholangitis. The majority of the patients who are candidates for surgical resection in GBC with jaundice require preoperative drainage to optimize liver function. Biliary drainage can be achieved through percutaneous transhepatic biliary drainage (PTBD), endoscopic biliary drainage (EBD), and surgical bypass. Surgical bypass is less preferred due to the invasiveness of the procedure, and EBD or PTBD is carried out in the majority of the cases [13]. Endoscopic drainage is more technically demanding and associated with a higher incidence of cholangitis, and the success rate varies
from 40 to 80% in hilar obstructions [14–16]. In many centers, PTBD is a preferred approach for proximal or hilar obstruction [17]. PTBD is an effective drainage method but associated with significant complications that include occlusion, dislodgement, cholangitis, peri-catheter leakage, and bleeding. These complications are possibly underreported in the literature [10, 18, 19], though PTBD is the preferred method for palliation, and there is limited literature with conflicting results on its associated complications and its impact on quality of life (QoL) [17].

Therefore, we conducted a prospective study to determine the outcome, overall complications, and quality of life (QoL) after PTBD in carcinoma gallbladder patients presenting with obstructive jaundice.

**Material and Methods**

**Study Design and Patient Population**

This study is a prospective observational study and conducted at a tertiary care center in northern India. The institute’s ethical committee approved the study protocol before the recruitment of patients. Written informed consent was obtained from each participant before inclusion. We enrolled patients with obstructive jaundice due to carcinoma gallbladder presenting to us from July 2018 to December 2019. Clinico-demographic features, including comorbid conditions and preoperative laboratory parameters, were recorded. All patients underwent preoperative staging with cross-sectional imaging (contrast-enhanced computed tomography (CECT) abdomen or magnetic resonance imaging (MRI) or positron emission tomography (PET-CT)). The diagnosis of carcinoma gallbladder was based on clinical and radiological features. Tissue biopsy was done in patients who were planned for neoadjuvant or palliative chemotherapy. The staging was done as per AJCC 8th edition [20].

All patients underwent PTBD, and the common indications of PTBD were (a) cholangitis, (b) intractable pruritus, (c) patients planned for curative surgery with bilirubin level ≥ 5 mg/dl or poor nutritional status or impaired renal parameters or coagulation abnormalities, (d) patients planned for neoadjuvant therapy, and (e) palliative chemotherapy. Patients with benign etiology of jaundice, e.g., cholelithiasis, previously treated for carcinoma gallbladder, patients who underwent endoscopic drainage, and those who refused to participate in the study were excluded.

**PTBD Procedure**

All the baseline investigations, including hemoglobin, blood cell counts, serum electrolytes, renal function tests, and liver function tests, were done. All of the procedures were performed under local anesthesia using 2% of injection lignocaine. Under USG guidance, a peripheral bile duct was punctured using an 18G or a 21G puncture needle. After the free flow of bile through the puncture needle, 2–3 ml of diluted contrast material (omnipaque 50% dilution with normal saline) was gently injected under fluoroscopic guidance to visualize the ductal anatomy and the level of biliary obstruction. PTBD catheter (8F or 10F single pigtail) was placed over the guidewire in the ductal system after track dilatation. Left ductal system access was preferred over the right system. The PTBD catheter was fixed with the Centurion saddle technique. Patients were observed for a minimum of 24 h or more when needed and then discharged. The bile from the PTBD catheter was sent for culture with antimicrobial sensitivity.

The technical success of the procedure was confirmed by ultrasound examination to assess the decompression of the bile ducts and the nature and amount of drain output. Internalization of PTBD was attempted after 3 days or after complete resolution of cholangitis. All patients received injectable prophylactic antibiotic piperacillin + tazobactam 2 h before the procedure. Antibiotic was continued after the procedure in patients presenting with cholangitis or who developed post-procedure cholangitis, and antibiotics were changed according to bile culture sensitivity. No post-procedure antibiotic was given in patients without cholangitis.

**Post-PTBD Follow-up and Outcomes**

Patients with the potentially resectable disease were further investigated. Those who were planned for neoadjuvant or palliative chemotherapy were started on chemotherapy. Patients were followed up in the outpatient clinic, and PTBD-related complications and reintervention were recorded and managed.

**Assessment of Quality of Life**

We compared the patient’s quality of life in our study before placing the PTBD catheter and after 4 to 6 weeks post-procedure using the SF-36 questionnaire [21]. The patients were questioned about various aspects of their quality of life using a set of 36 questions which were subgrouped into nine topics, namely, role limitations due to physical health, role limitations due to emotional problems, physical functioning, emotional well-being, social functioning, energy/fatigue, general health, pain, and health change.

**Statistical Analysis**

The data were analyzed with the SPSS version 22.0 software. Continuous variables were expressed as arithmetic mean ± standard deviation (SD) or median (range), and they
were equated using the Student’s paired T-test and Wilcoxon signed-rank test wherever necessary. *P*-Value was taken as statistically significant if it was less than 0.05.

### Results

#### Study Population

During the study period, a total of 160 patients with carcinoma gall bladder were assessed for inclusion. Eighty-nine patients of GBC without jaundice, eight patients who underwent endoscopic drainage, and three patients who declined to participate in the study were excluded (Fig. 1). A total of 60 patients were included in the final analysis.

The clinic-demographic detail of the study population is summarized in (Table 1). The mean age of the study population was 53.7 ± 10.95 years; 27 (45%) were male. Eleven patients (18.3%) had metastatic disease at the time of presentation. The clinical presentation was with abdominal pain in 48 (80%) and fever in 21 patients (35%). The gall bladder lump was palpable in 33 (55%) patients, and 2 (3.3%) had ascites. The level of block was at hilum due to tumor infiltration, and in 35 (58.3%), patients there was separation of the biliary confluence.

#### PTBD Procedure and Its Complication

The left-sided PTBD was placed in 59 (98.3%) patients. Eight French (Fr) PTBD catheter was used in 59 (98.3%) patients and 10 Fr in one patient (1.6%). On follow-up, there was a significant decrease in the bilirubin level at six weeks post-procedure (14.94 ± 6.24 vs. 7.51 ± 4.33, (P ≤ 0.001). Only three patients had normal bilirubin level at the end of 6 weeks. The successful internalization of PTBD was done in 40 (67%) patients. No patient had immediate procedure-related complications. Forty-one (68%) had at least one complication following the PTBD procedure. Eighteen (30%) patients had more than one complication (Table 2). Reintervention was required in 32 (53%) patients. Out of these 32 patients, reintervention was required twice in eight patients and thrice in two patients. The indications and complications of the PTBD procedure are enumerated in Table 2. The most common complication was peri-catheter bile leak in 25 (41.6%) patients, and post-PTBD bleeding was seen in 6 (10%) patients. Three out of these six patients required size up-gradation of PTBD catheter to manage the bleed, and the rest three did not require any intervention.

![Flow chart of the study population](image)

**Table 1** Clinico-demographic detail of study population

| Total number of patients | 60 |
|--------------------------|----|
| Age, mean ± SD, years    | 53.7 ± 10.95 |
| Gender, male, n (%)      | 27 (45) |
| BMI, mean ± SD, kg/m²    | 21.88 ± 2.57 |
| Clinical presentation    |    |
| Fever, n (%)             | 21 (35) |
| Abdominal pain, n (%)    | 48 (80) |
| Palpable abdominal mass, n (%) | 33 (55) |
| Pruritus, n (%)          | 23 (38) |
| Left supraclavicular lymphadenopathy (LSC), n (%) | 2 (3) |
| Associated gall stone disease, n (%) | 36 (60) |
| Comorbidity              |    |
| Hypertension, n (%)      | 2 (3) |
| Diabetes mellitus, n (%) | 4 (6) |
| Staging                  |    |
| T3 disease, n (%)        | 38 (63) |
| T4 disease, n (%)        | 22 (36) |
| Metastatic disease, n (%)| 11 (18) |

**Table 2** Indications and complications of PTBD procedure

| Indications                                      | 21 (35) |
|-------------------------------------------------|---------|
| 1 Cholangitis, n (%)                            |         |
| 2 Intractable pruritus, n (%)                   | 23 (38) |
| 3 Planned neo-adjuvant treatment, n (%)         | 19 (31) |
| 4 Metastasis, n (%)                             | 11 (18) |
| Complications                                    |         |
| 1 Blockage of catheter, n (%)                   | 14 (23.3)|
| 2 Peri-catheter bile leak, n (%)                | 25 (41.6)|
| 3 Catheter slip out, n (%)                      | 18 (30) |
| 4 Bleeding, n (%)                               | 6 (10)  |
Follow-up Results

The median follow-up of the study population was 11.8 weeks with no PTBD complication-related mortality. Preoperative neoadjuvant or palliative chemotherapy was started in 7 patients. Only one patient completed the entire course of planned chemotherapy, while in the rest, chemotherapy could not be completed due to PTBD-related complications or poor functional status. Two patients were planned for surgical exploration. One patient underwent right extended hepatectomy with hepatic duct resection, and Roux-en-Y left hepaticojejunostomy. In another patient, resection was abandoned due to metastatic disease on staging laparoscopic. Thirty-seven (61%) patients expired within 6 months of diagnosis. The median survival in the study population was 12 weeks.

Bile Culture

PTBD bile cultures were sent immediately after the procedure. Eight (13%) patients had positive bile cultures, and *Escherichia coli* was the most common (50%) microorganism isolated from the bile. Among these eight patients, six patients developed post-PTBD cholangitis, which was managed with intravenous antibiotics, and additionally, two patients required PTBD catheter change due to partial blockage.

Quality of Life Score

All patients underwent QoL assessment before and after the PTBD placement. There was a significant decrease in the quality of life (SF-36) of the patients in all of the nine categories after PTBD catheter placement (Table 3). On subgroup analysis, quality of life (SF-36) was significantly decreased in both the metastatic and non-metastatic groups in all nine categories after PTBD catheter placement.

Table 3 Quality of life score

| Parameter                              | Before PTBD placement | After PTBD placement | P Value |
|----------------------------------------|-----------------------|----------------------|---------|
| 1 Physical functioning, mean ± SD      | 62.16 ± 18.78         | 28.25 ± 16.25        | <0.001  |
| 2 Role limitations due to physical health, mean ± SD | 60.83 ± 25.36         | 17.16 ± 18.04        | <0.001  |
| 3 Role limitations due to emotional problems, mean ± SD | 41.38 ± 27.25         | 14.99 ± 22.47        | <0.001  |
| 4 Energy/fatigue, mean ± SD            | 58.66 ± 10.53         | 22.58 ± 10.59        | <0.001  |
| 5 Emotional wellbeing, mean ± SD       | 59.50 ± 11.48         | 25.01 ± 10.38        | <0.001  |
| 6 Social functioning, mean ± SD        | 53.45 ± 14.57         | 24.37 ± 12.27        | <0.001  |
| 7 Pain, mean ± SD                      | 55.33 ± 13.92         | 16.75 ± 19.06        | <0.001  |
| 8 General health, mean ± SD            | 46.08 ± 10.24         | 16.75 ± 8.22         | <0.001  |
| 9 Health change, mean ± SD             | 44.58 ± 18.46         | 13.75 ± 13.36        | <0.001  |

Discussion

The present study demonstrates that percutaneous transhepatic biliary drainage is a standard procedure used to relieve obstructive jaundice in malignant biliary obstruction secondary to carcinoma gallbladder and is an effective modality to improve hyperbilirubinemia. The common indications of biliary drainage were palliation of symptoms, cholangitis, planned major liver resection, and chemotherapy. However, this comes with a significant complication rate and does not improve the QoL of these patients. The post-PTBD overall median survival was 12 weeks. The study points to a need to improve biliary drainage techniques and post-PTBD care, reducing the complication rates.

With the advent of minimally invasive techniques, PTBD and ERCP are well-established and effective methods of biliary drainage. PTBD is the preferred procedure in proximal obstruction, and it increases the success of biliary drainage and reduces the risk of cholangitis [22]. It can be done under minimal sedation, hence feasible in unstable patients also [13, 23]. Unfortunately, the procedure is associated with complication rates of 40–50% in retrospective studies, with occlusion, dislodgement, cholangitis, and peri-catheter leak being the most frequently reported complications [18, 24]. In our study, at least one PTBD-related complication was observed in 68% of patients. Peri-catheter bile leak (41.6%), catheter slip out (30%), catheter blockage (23.3%) were the common complications. The hanging external PTBD catheter and catheter blockage are important risk factors for most of these complications. The early internalization of the PTBD catheter in the absence of cholangitis and flushing of the catheter with normal saline and appropriate post PTBD care might help in mitigating these complications.

A randomized study compared PTBD procedure with ERC drainage in the carcinoma gallbladder showed improved outcome in the form of a better success rate and low incidence of cholangitis but did not show a significant change in the quality of life PTBD group as compared to...
the ERCP group [10]. Various studies evaluated the QoL after PTBD in malignant hilar obstruction and showed a significant decrease in quality of life after PTBD [22, 25]. However, these studies are limited by heterogeneous populations with different etiologies of hilar obstruction. Our study focused on patients with carcinoma gallbladder; the QoL decreased in all nine subcategories of SF-36 questionnaires after PTBD. The higher complication rate and increased reintervention rates contributed to the significant decrease in QoL.

In our study, we were able to do curative resection in only one patient out of the seventeen patients who were planned for resection. The reported incidence of curative resection in carcinoma gallbladder with jaundice is 7–30% [5, 7, 8, 26]. The low resection rate in GBC with jaundice is due to aggressive tumor behavior with a high incidence of metas-tasis and further compounded by the complications associated with drainage procedure. In our study, PTBD-related complications and interventions delayed the initiation and completion of chemotherapy, contributing to the poor overall outcome. Despite these complications, PTBD has a significant role in palliation and treatment of proximal biliary stricture. The provision of better post-intervention care and patient education is crucial to decrease these complications. This is a major challenge in a low-income country with the poor socio-economic background of the patient population.

To conclude, jaundiced patients with underlying carcinoma gallbladder have a higher incidence of locally advanced and metastatic disease. Biliary drainage procedure should be performed with the aims of relieving symptoms, improving QoL, and enabling further chemotherapy treatments. The higher technical success rate of PTBD does not translate into the improvements of QoL. The role of PTBD merely as a palliative procedure is limited because of morbidity associated with the procedure and lack of improvement in QoL. However, improved technical expertise, drainage techniques, and adequate post-procedural care of PTBD might help in improving the outcomes.

**Author Contribution** Study concept and design: HS, VNS. Data acquisition: HS, VNS, TDY, MA, HK, UG. Data analysis: HS, VNS, MA, VS, HM. Drafting the manuscript: HS, VNS, TDY, VS, HM. Supervision: HS, TDY, UG, HK.

**References**

1. Takada T, Amano H, Yasuda H, Nimura Y, Matsuhiro T, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.
2. Mayo SC, Shore AD, Nathan H, Edil B, Wolfgang CL, Hirose K, et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg. 2010;14:1578–91.
3. D’Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16:806–16.
4. Grobmyer SR, Lieberman MD, Daly JM. Gallbladder cancer in the twentieth century: single institutions experience. World J Surg. 2004;1(28):47–9.
5. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.
6. Redaelli C, Buchler MW, Schiing CK, Krahenbuhl L, Ruchti C, Blumgart LH, et al. High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery. 1997;121:58–63.
7. Tran TB, Norton JA, Ethun CG, Pavlik TM, Buettner S, Schmidt C, et al. Gallbladder cancer presenting with jaundice: uniformly fatal or still potentially curable? J Gastrointest Surg. 2017;21:1245–53.
8. Mishra PK, Saluja SS, Prithiviraj N, Varshney V, Goel N, Patil N. Predictors of curative resection and long term survival of gallbladder cancer – a retrospective analysis. Am J Surg. 2017;214:278–86.
9. Agarwal AK, Mandal S, Singh S, Bhojwani R, Sahuju P, Uppal R. Biliary obstruction in gall bladder cancer is not sine qua non of inoperability. Ann Surg Oncol. 2007;14:2831–7.
10. Saluja S, Gulati M, Garg P, Pal H, Pal S, Sahni P, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol. 2008;6:944–50.
11. Nishio H, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection: Ann Surg. 2011;253:953–60.
12. Regimbeau JM, Fuks D, Bachellier P, Le Tret YP, Pruvot FR, Navarro F, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. Eur J Surg Oncol EJSO. 2011;37:505–12.
13. Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V, et al. Endoscopic versus percutaneous biliary drainage in palliation of advanced malignant hilar obstruction: a meta-analysis and systematic review. Can J Gastroenterol Hepatol. 2016;2016:1–8.
14. Sherman S. Endoscopic drainage of malignant hilar obstruction: is one biliary stent enough or should we work to place two? Gastrointest Endosc. 2003;53:681–4.
15. Walter T, Ho CS, Horgan AM, Warkentin A, Gallinger S, Greig PD, et al. Endoscopic or percutaneous biliary drainage for Klatskin tumors? J Vasc Interv Radiol. 2013;24:113–21.
16. Paik WH, Park YS, Hwang J-H, Lee SH, Yoon CJ, Kang S-G, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc. 2009;69:55–62.
17. Crosara Teixeira M, Mak MP, Marques DF, Caparelli F, Carnevalle FC, Moreira AM, et al. Percutaneous transhepatic biliary drainage in patients with advanced solid malignancies: prognostic factors and clinical outcomes. J Gastrointest Cancer. 2013;44:398–403.
18. Nennstiel S, Weber A, Frick G, Haller B, Meining A, Schmid RM, et al. Drainage-related complications in percutaneous transhepatic biliary drainage: an analysis over 10 years. J Clin Gastroenterol. 2015;49:764–70.
19. Chu D, Adler DG. Malignant biliary tract obstruction: evaluation and therapy. J Natl Compr Canc Netw. 2010;8:1033–44.
20. Amin MB, Gres DM, Meyer LR, Edge SB, Greene FL, Byrd DR, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
22. Mansfield S. Management of hilar cholangiocarcinoma in the North of England: Pathology, treatment, and outcome. World J Gastroenterol. 2005;11:7625.

23. Gupta P, Maralakunte M, Rathee S, Samanta J, Sharma V, Mandavdhare H, et al. Percutaneous transhepatic biliary drainage in patients at higher risk for adverse events: experience from a tertiary care referral center. Abdom Radiol (NY). 2020;45:2547–53.

24. Knap D, Orlecka N, Judka R, Juza A, Drabek M, Honkowicz M, et al. Biliary duct obstruction treatment with aid of percutaneous transhepatic biliary drainage. Alex J Med. 2016;52:185–91.

25. Robson PC, Heffernan N, Gonen M, Thornton R, Brody LA, Holmes R, et al. Prospective study of outcomes after percutaneous biliary drainage for malignant biliary obstruction. Ann Surg Oncol. 2010;17:2303–11.

26. Dasari BVM, Ionescu MI, Pawlik TM, Hodson J, Sutcliffe RP, Roberts KJ, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: a systematic review and meta-analysis. J Surg Oncol. 2018;118:477–85.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.